Antifibrinolytic Drugs Market Report 2026

The antifibrinolytic drugs market size has grown strongly in recent years. It will grow from $17.84 billion in 2025 to $18.9 billion in 2026 at a compound annual growth rate (CAGR) of 6%. The growth in the historic period can be attributed to expansion of surgical intervention volumes, increased awareness of perioperative bleeding control, availability of generic antifibrinolytic drugs, clinical validation in trauma care, adoption in gynecological treatments.

The antifibrinolytic drugs market size is expected to see strong growth in the next few years. It will grow to $23.54 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to increasing demand from ambulatory surgical centers, rising focus on patient blood management programs, expansion of emergency care infrastructure, growing use in orthopedic and cardiovascular surgeries, continued development of safer formulations. Major trends in the forecast period include increasing use of antifibrinolytics in surgical procedures, rising adoption in trauma and emergency care, expansion of oral and injectable formulations, growing focus on blood loss management, enhanced clinical protocol standardization.

The increasing number of surgical procedures is expected to drive the growth of the antifibrinolytic drugs market moving forward. Surgical procedures are on the rise due to factors such as advancements in medical technology, an aging population, increased awareness, and cultural and social influences. Antifibrinolytic drugs help reduce bleeding during surgery by preventing the breakdown of blood clots, improving hemostasis, and potentially decreasing the need for blood transfusions. For example, in 2023, the International Society of Aesthetic Plastic Surgery, a US-based professional body, reported that the total number of surgical and non-surgical procedures increased by 3.4%, reaching 34.9 million. As a result, the growing number of surgical procedures is contributing to the expansion of the antifibrinolytic drugs market.

Leading companies in the antifibrinolytic drugs market are focusing on innovative solutions, such as the first-to-consumer approach, to offer easily accessible treatments for women. The first-to-consumer approach involves marketing these medications directly to patients rather than through traditional healthcare providers. For instance, in May 2024, Maxwellia Ltd., a UK-based healthcare company, launched two new pharmacy brands - Evana Heavy Period Relief 500 mg tablets and Ultravana Period Pain Relief 250 mg gastro-resistant tablets. Evana reduces heavy menstrual bleeding by up to 60%, while Ultravana provides effective relief for period pain. Both products are available without a prescription in UK pharmacies, helping women manage common but often overlooked menstrual issues.

In September 2025, A.forall, a Belgium-based manufacturer of sterile injectable generics, acquired Provepharm’s U.S. generics portfolio for an undisclosed amount. With this acquisition, A.forall aims to expand its hospital-use injectable business, including antifibrinolytic drugs like tranexamic acid, and strengthen its presence in the U.S. generics market. Provepharm, based in the U.S., provides sterile injectable generics, including tranexamic acid.

Major companies operating in the antifibrinolytic drugs market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Bayer AG, DAIICHI SANKYO COMPANY LIMITED, Sun Pharmaceutical Industries Ltd, Takeda Pharmaceuticals, Aurobindo Pharma Limited, Cipla Limited, Intas Pharmaceuticals, Lupin Limited, Zydus Lifesciences Ltd., Hetero Drugs Limited, Glenmark Pharmaceuticals, Alkem Laboratories, Torrent Pharmaceuticals Ltd, Macleods Pharmaceuticals Pvt Ltd, Mankind pharma Ltd, Emcure Pharmaceuticals ltd, Bharat Serums & Vaccines Ltd, Systopic Laboratories Pvt Ltd, Ozone Pharmaceuticals Ltd, ACIC Pharmaceuticals, AmeriGen Life Sciences LLP, Life Sciences Advanced Technologies Inc., Vitruvias Therapeutics Inc.

North America was the largest region in the antifibrinolytic drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antifibrinolytic drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the antifibrinolytic drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the antifibrinolytic drugs market by increasing costs of imported active pharmaceutical ingredients, excipients, sterile packaging materials, and pharmaceutical manufacturing equipment. Hospitals and drug manufacturers in North America and Europe are most affected due to reliance on international api supply chains, while Asia-Pacific faces cost pressures in generic drug exports. These tariffs are increasing production expenses and influencing drug pricing strategies. However, they are also encouraging domestic api manufacturing, regional pharmaceutical investments, and supply chain diversification to ensure consistent drug availability.

The antifibrinolytic drugs market research report is one of a series of new reports that provides antifibrinolytic drugs market statistics, including antifibrinolytic drugs industry global market size, regional shares, competitors with a antifibrinolytic drugs market share, detailed antifibrinolytic drugs market segments, market trends and opportunities, and any further data you may need to thrive in the antifibrinolytic drugs industry. This antifibrinolytic drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Antifibrinolytic drugs are medications that prevent the breakdown of blood clots by inhibiting enzymes such as plasmin, which are essential for controlling excessive bleeding. These drugs are used to treat or prevent bleeding in conditions such as hemophilia, heavy menstrual bleeding, and during surgeries where significant blood loss is anticipated.

The primary indications for antifibrinolytic drugs include gynecology, hereditary angioedema, fibrinolytic response testing, surgeries, and other related conditions. Gynecology, the branch of medicine focused on the female reproductive system, involves using these medications to manage bleeding issues associated with gynecological conditions or surgeries. These drugs can be administered through various routes, including injectable, oral, and topical methods. They are utilized by a wide range of end users, including hospitals, clinics, ambulatory surgical centers, and trauma centers.

The antifibrinolytic drugs market consists of sales of tranexamic acid, aminocaproic acid, aprotinin, epsilon-aminocaproic acid, and desmopressin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.